Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 8/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136152 | 0.90 | BMP1 (0.39) | BMP1TRPV4ALOX5APFEN1CCR1 | |
| SCHEMBL4141037 | 0.80 | BMP1 (0.37) | BMP1TRPV4CCR1ADAM17MAPT | |
| SCHEMBL4136278 | 0.80 | BMP1 (0.39) | BMP1TRPV4CCR1ADAM17 | |
| SCHEMBL4136447 | 0.80 | TRPV4 (0.50) | BMP1ACKR3HPGDSTRPV4TP53 | |
| SCHEMBL5435367 | 0.79 | BMP1 (0.40) | BMP1TRPV4CCR1ADAM17 | |
| SCHEMBL4140703 | 0.78 | TRPV4 (0.37) | BMP1TRPV4CCR1ADAM17 | |
| SCHEMBL4133715 | 0.78 | CCR1 (0.36) | BMP1TRPV4TP53CCR1ADAM17 | |
| SCHEMBL4136298 | 0.78 | CCR1 (0.38) | BMP1TRPV4CCR1CAPN1ADAM17 | |
| SCHEMBL4135938 | 0.78 | BMP1 (0.36) | BMP1TRPV4CCR1CAPN1ADAM17 | |
| SCHEMBL4128102 | 0.78 | TRPM8 (0.40) | ACKR3TRPV4CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | BMP1 2172/4885ACKR3 143/4885HPGDS 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.